Vertex Pharmaceuticals Incorporated which can be found using ticker (VRTX) now have 25 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $500.00 and $325.00 suggesting an average Analsyt target price of $411.64. Now with the previous closing price of $408.05 this now indicates there is a potential upside of .9%. The day 50 moving average is $370.74 and the 200 day MA is $348.81. The total market capitalization for the company now stands at 105.46B. The stock price for the company is currently $409.27 USD
The potential market cap would be $106,389,771,669 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 30.77, revenue per share of $37.49 and a 14.34% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
